Clinical trials: Investigation Time
Migraine
A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.
This is a double-blind randomised controlled study to evaluate the effectiveness of orally-dosed Palmitoylethanolamide (PEA) compared to placebo for reducing pain severity and duration of migraines in otherwise healthy…
- Trial name
- NCT05046522
- Testing
- Palmitoylethanolamide sold as Levagen +
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- RDC Clinical Pty Ltd
Diphtheria, Tetanus
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when…
- Conditions
- Diphtheria, Tetanus, Haemophilus Infection, Pertussis
- Trial name
- NCT00772928
- Testing
- Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
- Where
- 23 sites in United States
- Volunteers
- 1,167 people, healthy volunteers welcome
- Sponsor
- Sanofi
Burns
Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds
The main goal of this phase III clinical trial is to show safety and efficacy of Oleogel-S10 in the acceleration of wound healing of grade 2a burn wounds.
- Trial name
- NCT01657292
- Testing
- Oleogel-S10 ointment, Octenilin® wound gel
- Where
- 9 sites in Germany, Sweden and 2 more
- Volunteers
- 61 people
- Sponsor
- Birken AG
Healthy
Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants
The purpose of the study is to evaluate the effects of JNJ-42847922, compared to zolpidem and placebo, on driving performance as assessed by the mean difference of standard deviation of lateral position (SDLP) after forced…
- Trial name
- NCT02578472
- Testing
- JNJ-42847922, Zolpidem
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Sudden Cardiac Death, Sudden Cardiac Arrest
Time and Dose Evaluation of Stearidonic Acid (SDA) to Eicosapentaenoic Acid (EPA) in Red Blood Cells
The purpose of this study is to assess the relationships between dose and time of consumption of stearidonic acid (SDA) and eicosapentaenoic acid (EPA) on EPA enrichment of red blood cell (RBC) membranes in men and women.
- Conditions
- Sudden Cardiac Death, Sudden Cardiac Arrest, Cardiovascular Disease
- Trial name
- NK (NCT01038440)
- Testing
- Safflower Oil, EPA, SDA
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Solae, LLC
Diabetes Mellitus, Type 2
A Study of GZR18 Tablet in Chinese Healthy Subjects
The aim of the trial is to investigate the the bioavailability, pharmacokinetics, pharmacodynamics, safety and tolerance of single and multiple doses of GZR18 tablet in healthy subjects.
- Trial name
- NCT06554054
- Testing
- GZR18
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Chronic Plaque Psoriasis
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic…
- Trial name
- NCT03025542
- Testing
- Bimekizumab
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
- Trial name
- NCT06768671
- Testing
- Sonelokimab
- Where
- 18 sites in United States
- Volunteers
- 35 people
- Sponsor
- MoonLake Immunotherapeutics AG
Type 1 Diabetes Mellitus
Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus
Primary Objective: To assess the dose-response pattern of the glucose consumption (GIR-AUC0-end) of 3 different single doses of Afrezza inhaled Technosphere insulin and of 3 single doses of subcutaneous (SC) insulin lispro in a…
- Trial name
- NCT02470637
- Testing
- SAR439065, Insulin lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
Ankle Sprain
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain
The purpose of this study is to evaluate the efficacy of Diclofenac Sodium Topical (DSG) 1% compared with placebo applied four times a day in subjects with acute ankle sprains under 'in-use' conditions, in particular with regard…
- Trial name
- NCT01255423
- Testing
- Diclofenac sodium topical gel 1%
- Where
- 9 sites in United States
- Volunteers
- 206 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
The purpose of the study was to demonstrate if iGlarLixi (Soliqua 100/33) would improve glycemic control (as measured by Time in Range) and glycemic variability in participants with very uncontrolled (HbA1c ≥ 9%) type 2 Diabetes…
- Trial name
- Soli-CGM (NCT05114590)
- Testing
- Insulin glargine/Lixisenatide
- Where
- 18 sites in United States
- Volunteers
- 124 people
- Sponsor
- Sanofi
Cerebral Arterial Diseases
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
- Trial name
- NCT01012674
- Testing
- Dotarem, TOF MRA
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- Guerbet
Oedema, Pulmonary
A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients
This study is the first administration of GSK2798745 in humans. This will be a sponsor un-blinded, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSK2798745…
- Trial name
- NCT02119260
- Testing
- GSK2798745 solution, GSK2798745 suspension, GSK2798745 capsule
- Where
- 2 sites in United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dyslipidemia, Hyperlipidemia
Rosuvastatin Adherence App Study in China
This is a randomized, two-arm, open label, Phase IV clinical trial to evaluate if the provision of a smart phone-based patient support tool prolongs the patient's rosuvastatin treatment duration.
- Trial name
- eHELP China (NCT02433288)
- Testing
- Smart phone based patient support tool, Control application: only for data collection
- Where
- 25 sites in China
- Volunteers
- 885 people
- Sponsor
- AstraZeneca
Multiple Sclerosis
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and…
- Trial name
- NCT01085318
- Testing
- Rebif
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- EMD Serono
Healthy
Nurofen Ibuprofen Orodispersible Tablet Disintegration Study
Disintegration time is an important quality attribute of ODTs, and the evaluation of disintegration time is positioned as a key step in formulation development, manufacturing, and clinical practice.
- Trial name
- NCT03658720
- Testing
- 200 mg Ibuprofen acid orodispersible tablet
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Infection, Human Immunodeficiency Virus
Single Dose Escalation Study of GSK2838232 in Healthy Subjects
GSK2838232 is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection. This study is the first administration of GSK2838232 in humans to establish the initial safety…
- Trial name
- NCT01802918
- Testing
- GSK2838232, Ritonavir
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix.
- Trial name
- NCT04161482
- Testing
- Furosemide 80 mg (8 mg/mL)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- scPharmaceuticals, Inc.
Ulcerative Colitis
Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis
The primary objective of the study was to compare the percentage of subjects in remission after 8 weeks of treatment with SPD476, 2.4 g/day once daily vs placebo and SPD476 4.8 g/day once daily versus placebo
- Trial name
- NCT00548574
- Testing
- SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine, Mesalazine
- Where
- Belgium
- Volunteers
- 343 people
- Sponsor
- Shire